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Abstract 
Oral anticoagulation therapy, largely performed by 
warfarin-based drugs, is commonly used for patients 
with a high risk of blood clotting which can lead to 
stroke or thrombosis. The state of the patient, with 
respect to anticoagulation, is captured by the index 
INR, which is to be kept within a therapeutic range. 
The patients’ response is marked by high inter-
individual and inter-temporal variability, which can 
lead to serious adverse events. Polymorphisms of two 
genes CYP2C9 and VKORC1, considered markers of 
lower dosage requirements, still account for a 
relatively minor part of this variability. In this work, 
authors show that classification methods can identify 
groups of patients homogeneous with respect to the 
dynamics of INR. In particular, authors use 
classification methods in order to characterize patients 
according to their warfarin metabolism and hence 
their sensitivity to different doses. Finally a Markov 
model to capture the dynamics of the patient’s 
response over the years is proposed.   
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1. Introduction 
Warfarin and its companion anticoagulant drugs are the 
first line treatment to mitigate the risks related to atrial 
fibrillation, ventricular dysfunction, deep vein 
thrombosis and aortic valve replacement. However 
their therapeutic range is very narrow: therefore 
frequent sampling (at least once in 2-3 weeks) of the 
INR index (International Rationalized Ratio), i.e. the 
time required for the blood to clot, and careful dosage 
adjustments are needed for the INR to stay within its 
assigned range. 
The “trial &error”  basis of the methods currently in 
use to fine tune the dosage for a given patient along 
with the response’s variability due to genetic and 
behavioral factors can result in out of range periods and 
therefore in a non negligible risk of thromboembolic 
and bleeding events. Warfarin initiation is associated 
with one of the highest adverse events for any single 
drug due to high inter-individual variability. About 
50% of patients fail to stabilize within the therapeutic 
range: for this reason most of these patients even with 
no contraindication to warfarin therapy are not 
receiving it because physicians are reluctant to initiate 
it in patient’s elderly or with risk of bleeding.  
Genotyping of patients has been recently suggested in 
order to understand inter-individual variability and 
control its dose-INR relationship, particularly in the 
induction phase. This fact as been recognized by FDA 
whose labeling for Warfarin 2007 reads: “It cannot be 
emphasized too strongly that the treatment of each 
patient is a highly individualized matter”.  A notable 
contribution to patient genotyping is: [14] where it is 
shown that genetics variants of the enzyme that 
metabolized Warfarin cytochrome P450 CYP2C9 and 
VKORC1 contribute to differences in patients’ 
response. Basically the same results have been obtained 
in a wide range of genetics investigations. More 
recently [3][12][15] variance of a new gene CYP4F2 
have been shown to alter warfarin requirements. 
While there is a relative large agreement of the 
value of genotypes for the induction phase, the debate 
is still open on its effectiveness in the long term 
therapeutic management [7]. Indeed in [1] it is shown 
that pharmacogenomics guided dosing failed to achieve 
a reduction of the patient average percentage INR 
outside the therapeutic range. 
This paper has two objectives: 
1. Use data mining techniques in order to characterize 
patients according to their warfarin metabolism and 
hence their sensitivity to different doses. 
2. Develop a Markov model to capture the dynamics 
of the patients response over the years 
 
Section 2 explains in detail the data sources and its 
preparation. The data mining algorithms are considered 
in Sect. 3 along with their results. Sect.4 is devoted to 
the Markov model, while sect.5 presents a 
comprehensive assessment of the results along with 
further research direction. 
 
2. Data sources 
We tested our approach on a sample of 1013 elderly 
(65+) patients. We imported data collected from the 
computerized databases in a database with three 
entities: patients, treatments and visits. For each patient 
we have information about date of birth, sex, medical 
evidence leading to OAT (Atrial Fibrillation, Deep 
Venous Thrombosis, other), patient’s INR range (2-3, 
2.5-3.5, 2.5-3) and target INR.  
Furthermore, for each patient, we memorize the 
concurrent medications in the treatment entity. In 
particular, we classified all treatment in different 
categories: digitalis, amiodarone, furosemide, nitrates, 
beta blockers, calcium channel blockers, ACE 
Inhibitors, diuretic tiazidic, sartanic, farmaco lipidi and 
other. So for each patient and for a particular category, 
we have a value “yes” if patient assumes a drug belong 
to this category and value “no” otherwise.  
Finally, for each visit we collected the date of visit, the 
result of the INR measurement, the weekly dose and 
the dose calendar, the drug used for OAT therapy 
(Coumadin 5 mg, Sintrom 1 or 4 mg). 
For a subset of patients we collected in the patient 
entity genomic data. In particular the polymorphism of 
CYP2C9 and VKRC01 are collected. For each patient 
CYP2C9 gene feature can have the following values: 
WT (wild Type), CT (*2 allele: the SNP in exon 3 
(CGT->TGT; Arg144Cys)), AC (*3 allele: the SNP in 
exon 7 (ATT->CTT; Ile359Leu)). The possible 
variants for gene VKORC1 are: WT (wild type), CT 
and TT. 
Thus each patient is characterized by 23 features. 
Entry characteristics for both 1013 patients and the 
subset of 135 patients with genomic data are 
summarized in Table 1: 
 
Tab. 1:principal characteristic of studied population 
Characteristics Patients without genomic data 
Patients with  
genomic data 
Patients number 1013 138 
Age, y, mean (dev.std) 76 (10) 76 (11) 
Gender: 
Women N(%) 502 (49.5%) 59 (43.70%) 
Men N(%) 511 (50.44%) 76 (56.30%) 
Primary reason for anticoagulation, N(%) 
Atrial fibrillation 771 (76.11 %) 135 (98.0%) 
Deep vein thrombosis 80 ( 7.9%) 1 (0.75 %) 
Other diagnosis 162 (15.99 %) 2 (1.35%) 
Clinical Variables: 
Target INR, mean (SD) 2,56 (0.2) 2,50 (0.3) 
Takes amiodarone, N (%) 175 (17.20%) 26 (19,25%) 
Takes ASA (acetylsalicylic acid), 
N(%) 
110 (10.85%) 15 (11.11%) 
Takes Farmaco Lipidi, N(%) 213 (21.02%) 29 (21.48%) 
 
The sample shows a prevalence of atrial fibrillation 
(76.11%). The genotyped sub-sample mirrors in a 
balanced way the relative weight of the features in the 
large one. In our study we extract from the 138 
patients, only those with atrial fibrillation and so we 
work on a dataset of 135 patients. 
The allelic variant frequencies for the subset of 135 
patients are summarized in Table 2. 
Tab. 2: Allelic variant frequencies 
Allelic variant frequencies 
CYP2C9 WT 66.67% 
 CT 20.74% 
AC 12.59% 
 
VKORC1 WT 33.33% 
 CT 40.74% 
TT 25.93% 
The overall allelic frequency distribution is similar to 
what is reported in the literature [1][5]. 
 
3. The data mining algorithms 
 
In this work, we introduce a particular index, called 
drug sensitivity (Dsens) to capture the dose-INR 
relationship which better characterizes the patient 
behavior. This index is represented by the ratio 
between dose and INR’s variations, as follows: 
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As INR measurements are not taken at regular intervals 
the dose values are replaced by their daily variations 
(∆di), and the INR values by ∆INRi (computed with the 
above formula) where Nd is the number of days 
between successive measurements. Note that a negative 
value of Dsens means that patient is not responding to 
the therapy because increasing (decreasing) doses are 
likely to correspond to decreasing (increasing) INR 
values. In this case a high absolute value of Dsens 
correspond to patients whose response in highly 
unpredictable. Positive values of Dsens indicate that 
patient is responding to the therapy, in this case the 
absolute value indicate the response sensitivity with 
respect to the dosage, patients falling in this class have 
a more predictable drug response behavior. 
In our study we compute the drug sensitivity index 
(Dsens) by using 6 dose-INR measurement time courses. 
Fig. 1 shows the empirical distribution of this variable. 
Three principal drug sensitivity’s classes (Negative [-
125 ≤ Dsens≤ -3,738], Medium [-3.738 ≤ Dsens< 7.38], 
Positive [7.38 < Dsens ≤ 107]) are obtained by 
discretizing the variable by using the minimum 
description length approach. 
 
 
Fig. 1: Drug Sensitivity distribution 
In particular, 123 patients belong to Negative Dsens 
class, 572 patients belong to Medium Dsens class and 
finally, 318 patients belong to Positive Dsens class. 
 
3.1 Clustering 
In particular, since data are both categorical and 
numerical, we use a modified k-prototypes algorithm, 
proposed by Bushel et al. [2], following an earlier 
paper of Huang [9], for handling mixed data.  In Fig. 2 
is represented the components of the modified k-
prototypes algorithm for our mixed numeric and 
categorical dataset. The approach follows the k-means 
paradigm with randomization of initialization of the 
algorithm. The strategy involves constructing an 
objective function from the sum of the squared 
Euclidean distances for numeric data with simple 
matching for categorical values in order to measure 
dissimilarity of the samples. Furthermore, separate 
weighting terms are used to control the influence of 
each data domain on the clustering of the patients.  
A cluster's prototype is formed from the mean of the 
values for numeric features and the mode of the 
categorical values of all the samples in the group. 
Finally, the dynamic validity index (DVI) for numeric 
data was modified with a category utility (CU) 
measure, obtaining a DVI_CU index. With this index 
we can determine the optimal number of clusters in the 
mixed type data, like in Bushel et al. [2]. The DVI_CU 
index is computed as: 
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The DVI index, proposed by Shen et al. [13], is based 
on an intra/inter ratio validity index that also includes 
scaling of the intra- and the inter-cluster distances. 
Furthermore, CU measure [8] defines the probability of 
matching a categorical feature value given a cluster 
versus the probability of the categorical feature value 
given the entire data set. 
 
Fig. 2: schema of the implemented algorithm 
 
In particular, DVI_CU is minimized over all k sets for 
each run of the modk-prototypes clustering algorithm.  
In our work, both the complete dataset and the genetic 
dataset are clustered using the modified k-prototypes 
clustering algorithm at values of k increasing from 2 to 
N, number of clusters. 
Values of DVI_CU index obtained for each value of k 
are reported in Fig. 3 and in Fig. 4. We have the 
minimum value of this index, for complete dataset, 
with k=3 and DVI_CU equals to 1.11, as represented in 
Fig. 3. Fig. 4 shown the results obtained on the dataset 
composed by patients with genetic data. In this case, 
minimum DVI_CU index is obtained with k=3 and 
DVI_CU equals to 1.08.  
Results of clustering algorithms confirm the division of 
patients into three different classes, as proposed in the 
last subsection. 
 
 
Fig. 3: DVI_CU index variation for k  
from 0 to 20 for complete dataset 
 Fig. 4: DVI_CU index variation for k  
from 0 to 20 for genomic dataset 
 
3.2 Drug sensitivity based classification 
Patient classification models, based on personal and 
clinical data, have been proposed in [4][10].However, 
the traditional machine learning applications on Oral 
Anticoagulation Therapy (OAT) problems, classifies 
patients on their average INR value (below, in and over 
patient range) but do not consider their drug sensitivity. 
In this paper we propose classification models using 
drug sensitivity index, explained above, as class 
variable. 
In order to build a classification model we considered 
the following features: personal data (age and gender), 
OAT therapeutic data (drug used for OAT therapy and 
medical evidence leading to OAT) and concomitant 
medications.  
We train and test, using 10-fold cross validation, four 
different machine learning classification algorithms 
(Multi Layer Perceptron (MLP), Support Vector 
Machines (SVM), K-Nearest Neighborhoods (kNN) 
and Bayesian Networks (BN)). For our experiments we 
use the Weka [16] implementation of the used 
classification algorithms. 
In this first stage we do not use INR average and 
variance. The model thus can be applied in the 
induction phase. 
Results in terms of correctly classified instances (CCI) 
and F-measure (the weighted harmonic mean of 
precision and recall) are shown in Tab. 3. 
 
Tab. 3: Dsens based classification results 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 60.61% 64.06% 59.32% 62.29% 
F-measure 0.581 0.595 0.578 0.589 
 
To characterize better the behavior of a patient we 
compute INR average and variance of a time course of 
6 INR measurements and include both these data in the 
feature set. So, we built new classification models with 
this new feature set and the obtained results, reported in  
Tab. 4, are better both in term of CCI and F-measure. 
Tab. 4: Dsens based classification results 
with new features 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 63.71% 68.70% 64.30% 64.46% 
F-measure 0.6214 0.613 0.598 0.611 
The model thus learned i.e. with the full set of features 
has been applied also in the induction phase i.e. 
without considering INR values. Obtained results are 
reported in Tab. 5.  
Comparing these results with those reported in Tab. 3, 
we can see that models learned using the two additional 
features about INR are better in term of CCI and f-
measure than those learned without these two features. 
 
Tab. 5: Dsens based classification results 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 61.61% 65.26% 60.88% 63.8% 
F-measure 0.5964 0.61 0.584 0.597 
 
3.3 Classification with Genetic data  
In this study we know genomic data of a subset (135 
patients) of the original 1013. We now present 
classification results obtained including two genomic 
features: 
• CYP2C9 polymorphism: this feature can assume 
value [WT,CT,AC] 
• VKORC1 polymorphism: this feature can assume 
value [WT,CT,TT] 
 Also with this dataset three different tests are 
performed, the same presented in subsection 4.2.  In 
the induction phase first stage we do not use INR 
average and variance. Results obtained at this step are 
reported in Tab. 6. 
 
Tab. 6: Dsens based classification with genomic data results. 
In this phase INR average and variance are not considered. 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 61.66% 65.6% 62.3% 63.5% 
F-measure 0.591 0.62 0.58 0.60 
 
Results obtained using the complete set of features 
(including INR average and variance) are reported 
inTab. 7. A new improvement is visible compared to 
the results inTab. 4.  
 
 
 
 
 Tab. 7: Dsens based classification  
with complete genomic data results 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 68.61% 74.41% 79.07% 75.58% 
F-measure 0.675 0.747 0.665 0.645 
 
Also in this case, the model thus learned i.e. with the 
full set of features has been applied also in the 
induction phase i.e. without considering INR values. 
Obtained results are reported in Tab. 8.  
 
Tab. 8: Dsens based classification with genomic data results. 
In this phase INR average and variance are not considered. 
 
DRUG SENSITIVITY 
based Classification 
MLP SVM kNN BN 
% CCI 62.2% 66.8% 63.1% 64.1% 
F-measure 0.62 0.64 0.60 0.625 
 
In this way we can see that genomic data allow a better 
characterization of patient’s behavior. 
 
Tab. 9: Genomic variant distribution  
in the three Dsens classes 
 
 
“Wild type” patients are predominantly in positive and 
medium drug sensitivity classes, as can be seen in Tab. 
9.  Patients with only one polymorphism are distributed 
principally in medium class and, finally, patients with 
variants on both genes are in negative class. To 
understand better the behavior of patients belonging to 
the three different classes we plot INR values of three 
different patients. In Fig. 5 are plotted INR values of a 
wild type patient belonging to the positive drug 
sensitivity class. Comparing this plot with that reported 
in figure Fig. 6, is possible to see that the hemorrhagic   
or thrombotic risk of a patient in negative Dsens class is 
higher then that of a positive Dsens patient. 
 
Fig. 5: Wild type patient (gene CYP2C9: WT; gene 
VK0RC1: WT), positive Drug Sensitivity class 
 
 
Fig. 6: Patient with two polymorphisms (gene CYP2C9:CT; 
gene VK0RC1:TT ), medium Drug Sensitivity class 
 
 
Fig. 7: Patient with two polymorphisms (gene CYP2C9: 
AC; gene VK0RC1:CT ),  negative Drug Sensitivity class 
  
4. The Markov model 
A Markov Chain (MC) is a discrete time stochastic 
process {Xk}, with a finite number of states and 
transition probability matrix. The simplest possible 
model of our problem considers: three states (HIGH 
(over range), IN (in range), LOW (under range)); three 
dosing actions (dose decrease, increase and constant) 
and a different transition probability matrix for each 
drug sensitivity class. Assessment of results is in Fig. 8, 
Fig. 9 and Fig. 10.  
 
Fig. 8: Transition matrices for negative Dsens class 
 
 
Fig. 9: Transition matrices for medium Dsens class 
 
 
Fig. 10: Transition matrices for positive Dsens class 
 
5. Assessments of results and future 
directions 
In this paper authors use different classification 
methods to characterize patients according to their 
warfarin metabolism and hence their sensitivity to 
different doses. Finally, through a Markov model they 
try to capture the dynamics of the patient’s response 
over the years. These promising results should be 
prospectively validated.  
Since all clinical studies so far failed to demonstrate a 
beneficial impact of pharmacogenetic guided warfarin 
dosing  and to achieve the primary end point reduction 
of out of range INR [7], we feel that an accurate patient 
characterization and subset analysis is required to 
capture how the dynamics of INR is impacted by the 
genomic patients’ features. The authors believe that a 
reduction in out of range time can be obtained through 
dosing approaches that capture this dynamic. 
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